ArticleAmerican journal of translational research2020
Effects of miR-22-3p targeted regulation of Socs3 on the hepatic insulin resistance in mice with gestational diabetes mellitus.
Article in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 8 citations in OpenAlex.
- MicroRNA-22-3p Regulates the Apoptosis of Lens Epithelial Cells Through Targeting KLF6 in Diabetic Cataracts.Translational vision science & technology · 2023Article
- The downregulation of miR-22 and miR-372 may contribute to gestational diabetes mellitus through regulating glucose metabolism via the PI3K/AKT/GLUT4 pathway.Journal of clinical laboratory analysis · 2022Article
- Optimization of miR-22 expression cassette for rAAV delivery on diabetes.Molecular biomedicine · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGestational diabetes mellitus (GDM) is one of the common complications of pregnant women, with serious threatening to pregnant women and newborns. The pathogenesis of GDM remains unclear now. This study aims to explore the effects of miR-22-3p targeted regulation of suppressors of cytokine signaling 3 (Socs3) on the hepatic insulin resistance (HIR) in mice with GDM.
methodsHealthy SPF C57BL/6J mice were selected to establish GDM model and divided into 7 groups: Normal group, Model group, NC-(negative control) mimic group, miR-22-3p mimic group, NC-pcDNA3.0 group, pcDNA3.0-Socs3 group, and miR-22-3p mimic + pcDNA3.0-Socs3 group. The islet morphology, and the expressions of miR-22-3p, Socs3 mRNA and Socs3 protein in the islet tissues were detected by HE staining, qRT-PCR and Western blot. Fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TC), and high-density lipoprotein cholesterol (HDL-C) were measured. Oral glucose tolerance test (OGTT) was performed to detect FBG and fasting insulin (FINS) contents, and insulin resistance (HOMA-IR) was calculated.
resultsCompared with the Normal group, the model group had decreased levels of miR-22-3p and HDL-C, while increased levels of Socs3 mRNA and protein expressions, OGTT, FBG, FINS, and HOMA-IR, TG and TC (all P < 0.05). Compared with the Model group, the above indicators (OGTT, FBG, FINS, HOMA-IR, TG, TC and HDL-C) were improved in the miR-22-3p mimic group, but worsened in the pcDNA3.0-Socs3 group (all P < 0.05).
conclusionmiR-22-3p can down-regulate the expression of Socs3, thereby inhibiting HIR in GDM mice.
Indexed as
Identifiers
33312367PMC7724336W3117829519What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.